source
- Lilly, Ascidian link up in RNA exon editing pactWorth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.BioPharma Dive · 1mo ago↗ source
- Top ultra-processed food researchers call for sweeping policy change: ‘The system is rigged’A survey finds that ultra-processed foods are a cross-partisan concern. And yet policy has been slow to follow.STAT · 1mo ago↗ source
- Opinion: The medical-billing AI arms race between providers and insurance“The financial side effects of care have become clinical ones,” writes Darshak Sanghavi.STAT · 1mo ago↗ source